Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuta Umezawa

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
IJU Case Reports|August 4, 2020
A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis-assisted transurethral resection involving orally administered 5-aminolevulinic acidKeitaro Watanabe, Suguru Shirotake, Yuta Umezawa, et al.
The Journal of Clinical Endocrinology and Metabolism|July 7, 2022
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell ResolutionNorifusa Iwahashi, Hironobu Umakoshi, Tsugio Seki, et al.
BJUI Compass|April 27, 2022
Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinomaTetsushi Murakami, Eiji Kikuchi, Hiroki Ide, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
IJU Case Reports|August 4, 2020
A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis-assisted transurethral resection involving orally administered 5-aminolevulinic acidKeitaro Watanabe, Suguru Shirotake, Yuta Umezawa, et al.
The Journal of Clinical Endocrinology and Metabolism|July 7, 2022
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell ResolutionNorifusa Iwahashi, Hironobu Umakoshi, Tsugio Seki, et al.
BJUI Compass|April 27, 2022
Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinomaTetsushi Murakami, Eiji Kikuchi, Hiroki Ide, et al.
Pageof 2